What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression
The DOI matches its Crossref record.
Abstract
The authors provide an overview of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a large-scale practical clinical trial to determine which of several treatments are the most effective "next-steps" for patients with major depressive disorder whose symptoms do not remit or who cannot tolerate an initial treatment and, if needed, ensuing treatments. Entry criteria were broadly defined and inclusive, and patients were enrolled from psychiatric and primary care clinics. All participants began on citalopram and were managed by clinic physicians, who followed an algorithm-guided acute-phase treatment through five visits over 12 weeks. At the end of each sequence, patients whose depression had not fully remitted were eligible for subsequent randomized trials in a sequence of up to three clinical trials. In general, remission rates in the study clinics were lower than expected, suggesting the need for several steps to achieve remission for most patients. There was no clear medication "winner" for patients whose depression did not remit after one or more aggressive medication trials. Both switching and augmenting appeared to be reasonable options when an initial antidepressant treatment failed, although these two strategies could not be directly compared. Further, the likelihood of remission after two vigorous medication trials substantially decreased, and remission would likely require more complicated medication regimens for which the existing evidence base is quite thin. STAR*D demonstrated that inclusion of more real-world patients in clinical trials is both feasible and informative. Policy implications of the findings, as well as the study's limitations, are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“low efficacy (only 27% of depressed patients achieved remission after 12 weeks of citalopram treatment as measured by HAM-D)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [259]
In the citing paper
“the current standard of care treatments suffer from slow onset (e.g., 7 week average response time with citalopram)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [259]
In the citing paper
“Studies examining antidepressant efficacy reveal 30% of depressed patients fail to respond to common antidepressant treatment (1)”
From Emerging Role for Nucleus Accumbens Medium Spiny Neuron Subtypes in Depression (2017) · cites this paper as [1]
In the citing paper
“Currently available antidepressant medications, alone and in combination, are associated with high rates of partial- or non-response, delayed response onset of weeks to months, and limited duration of efficacy5.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [5]
In the citing paper
“while more than a third fail to achieve remission even after several rounds of treatment ( Al-Harbi, 2012 , Gaynes et al., 2009 , Strawbridge et al., 2022 )”
From Self-blame-selective hyper-connectivity between anterior temporal and subgenual cortices predicts prognosis in major depressive disorder (2023) · cites this paper as Gaynes et al., 2009
Citations
Cites
Still being checked.
Cited by
Items 301–400 of 764
The emergence of antidepressant drugs targeting GABAA receptors: A concise review
Gonda, X., Tarazi, F. I., & Döme, P. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116481 · Cited by 19
Fava, M., Ramey, T. S., Pickering, E. H., Kinrys, G., Boyer, S., & Altstiel, L. D. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000245 · Cited by 19
Self-citationLv, D., Chen, Y., Shen, M., Liu, X., Zhang, Y., Xu, J., & Wang, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.046 · Cited by 19
Fabbri, C., & Serretti, A. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.4.484 · Cited by 19
Guo, F., Zhang, B., Fu, Z., Ma, Y., Gao, Y., Shen, F., Huang, C., & Li, Y. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.006 · Cited by 19
Cosci, F., Svicher, A., Romanazzo, S., Maggini, L., Cesaris, F. D., Benemei, S., & Geppetti, P. (2019) · CNS Spectrums · doi:10.1017/s1092852919001536 · Cited by 19
Cleare, A. J., Kerr-Gaffney, J., Goldsmith, K., Zenasni, Z., Yaziji, N., Jin, H., Colasanti, A., Geddes, J. R., Kessler, D., McAllister-Williams, R. H., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00028-8 · Cited by 18
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.003 · Cited by 18
Barnes, R., Skvarc, D., Fitzgerald, P. B., Berk, M., Dean, O. M., Dodd, S., Schriemer, T., & Singh, A. B. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110820 · Cited by 18
REM parameters in drug-free major depressive disorder: A systematic review and meta-analysis
Arıkan, M. K., Uysal, Ö., Gıca, Ş., Orhan, Ö., İlhan, R., Esmeray, M. T., Bakay, H., Metin, B., Pogarell, O. M., & Turan, Ş. (2023) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2023.101876 · Cited by 18
Fréret, T., Largillière, S., Née, G., Coolzaet, M., Corvaisier, S., & Boulouard, M. (2021) · Nutrients · doi:10.3390/nu13072445 · Cited by 18
Wu, P., Zhang, A., Sun, N., Lei, L., Liu, P., Wang, Y., Li, H., Yang, C., & Zhang, K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.751756 · Cited by 18
Toward an online cognitive and emotional battery to predict treatment remission in depression
Rekshan, W. R., Gordon, E., Palmer, D., Braund, T. A., & Rush, A. J. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75975 · Cited by 18
Self-citationNarendorf, S. C., Munson, M. R., & Floersch, J. E. (2015) · Journal of the Society for Social Work and Research · doi:10.1086/680318 · Cited by 18
Bristow, L. J., Gulia, J., Weed, M. R., Srikumar, B. N., Li, Y.-W., Graef, J. D., Naidu, P. S., Sanmathi, C., Aher, J., Bastia, T., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242784 · Cited by 18
Kahalnik, F., Sanchez, K., Faria, A., Grannemann, B. D., Jha, M. K., Tovian, C., Clark, E. W., Levinson, S., Pipes, R., Pederson, M., et al. (2018) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzy128 · Cited by 18
Self-citationGuo, F., Zhang, B., Shen, F., Li, Q., Song, Y., Li, T., Zhang, Y.-M., Du, W., Li, Y., Liu, W., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16420 · Cited by 17
Cichon, J., Joseph, T. T., Lu, X., Wasilczuk, A. Z., Kelz, M. B., Mennerick, S. J., Zorumski, C. F., & Nägele, P. (2025) · Nature Communications · doi:10.1038/s41467-025-57951-y · Cited by 17
Involvement of muscarinic receptor mechanisms in antidepressant drug action
Witkin, J. M., Smith, J. L., Golani, L. K., Brooks, E. A., & Martin, A. E. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.03.003 · Cited by 18
Flores, N. P., Bona, N. P., Luduvico, K. P., Cardoso, J. D. S., Soares, M. S. P., Gamaro, G. D., Spanevello, R. M., Lencina, C. L., Gazal, M., & Stefanello, F. M. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13442 · Cited by 17
Behavioral Patterns of Depression Patients and Control Population
Carreira-Míguez, M., Navarro-Jiménez, E., & Clemente‐Suárez, V. J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19159506 · Cited by 17
Koenig, L. J., Khurana, N., Islam, M. H., Gopalappa, C., & Farnham, P. G. (2023) · AIDS · doi:10.1097/qad.0000000000003536 · Cited by 17
Falkowska, M., Ntamati, N. R., Nevian, N. E., Nevian, T., & Acuña, M. A. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1139205 · Cited by 17
Clinical pharmacological innovation in the treatment of depression
Witkin, J. M., Golani, L. K., & Smith, J. L. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2198703 · Cited by 17
Public Health Insurance and Prescription Medications for Mental Illness
Maclean, J. C., Cook, B. L., Carson, N. J., & Pesko, M. F. (2018) · The B E Journal of Economic Analysis & Policy · doi:10.1515/bejeap-2018-0067 · Cited by 17
Østergaard, S. D., Speed, M. S., Kellner, C. H., Mueller, M., McClintock, S. M., Husain, M. M., Petrides, G., McCall, W. V., & Lisanby, S. H. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.039 · Cited by 17
Borderline Personality and Mood Disorders: Comorbidity and Controversy
Gunderson, J. G., & Choi-Kain, L. W. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1314-5 · Cited by 17
Targeting the GABAB Receptor for the Treatment of Depression and Anxiety Disorders
Felice, D., O’Leary, O. F., & Cryan, J. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-46044-4_12 · Cited by 17
Parikh, S. V., Voort, J. L. V., Yocum, A. K., Achtyes, E. D., Goes, F. S., Nykamp, L. J., Singh, B., Lopez-Vives, D., Sera, C. E., Maixner, D. F., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.12.033 · Cited by 16
Tseng, V. W.-S., Tharp, J. A., Reiter, J. E., Ferrer, W., Hong, D. S., Doraiswamy, P. M., Nickels, S., Schilsky, R. L., Allen, J., Anderson, M. A., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115702 · Cited by 16
Taraku, B., Loureiro, J. R., Sahib, A. K., Zavaliangos‐Petropulu, A., Al‐Sharif, N., Leaver, A. M., Wade, B., Joshi, S. H., Woods, R. P., Espinoza, R. T., et al. (2024) · Brain and Behavior · doi:10.1002/brb3.3511 · Cited by 16
The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice
Fleury, S., & Nautiyal, K. M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03387-1 · Cited by 16
Drago, A., & Serretti, A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182189c64 · Cited by 16
Treatment-Resistant Depression in Portugal: Perspective From Psychiatry Experts
Bessa, J. M., Carvalho, S., Cunha, I. B., Fernandes, M., Matos-Pires, A., Neves, R., Oliveira-Maia, A. J., Santos, S. G., & Santos, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.824919 · Cited by 16
Novel Antidepressant-Like Properties of the Iron Chelator Deferiprone in a Mouse Model of Depression
Uzungil, V., Tran, H., Aitken, C. M., Wilson, C., Opazo, C., Li, S., Payet, J. M., Mawal, C., Bush, A. I., Hale, M. W., et al. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01257-0 · Cited by 16
Castillo, A., Dubois, J., Field, R. M., Fishburn, F. A., Gundran, A., Ho, W. C., Jawhar, S., Kates‐Harbeck, J., Aghajan, Z. M., Miller, N., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38258-8 · Cited by 16
A New Regulatory Road-Map for Alzheimer’s Disease Drug Development
Becker, R. E., & Greig, N. H. (2014) · Current Alzheimer Research · doi:10.2174/156720501103140329210642 · Cited by 16
Magnesium and ketamine in the treatment of depression.
Górska, N., Słupski, J., Szałach, Ł. P., Włodarczyk, A., Szarmach, J., Jakuszkowiak‐Wojten, K., Gałuszko‐Węgielnik, M., Wilkowska, A., Wiglusz, M. S., & Cubała, W. J. (2019) · PubMed · Cited by 16
Jensen, K. J., Gronemann, F. H., Ankarfeldt, M. Z., Jimenez-Solem, E., Alulis, S., Riise, J., Bødker, N., Osler, M., & Petersen, J. (2022) · PLOS ONE · doi:10.1371/journal.pone.0275299 · Cited by 15
“It is a complex condition associated with comorbidities [7], higher risk of hospitalization and longer admission [8], increased suicidality and self-harm [9–11], increased risk of premature workforce exit [12], reduced quality of life, and poorer prognosis [13, 14] compared with nonTRD MDD patients.”
BackgroundTowards Personalised Mood Prediction and Explanation for Depression from Biophysical Data
Chatterjee, S., Mishra, J., Sundram, F., & Roop, P. (2023) · Sensors · doi:10.3390/s24010164 · Cited by 15
“However, they have a low effectiveness as only one-third of all patients show symptom remission, as evidenced in large clinical trials [3,4].”
Timäus, C., Vogelgsang, J. S., Kis, B., Radenbach, K., Wolff‐Menzler, C., Mavridou, K., Gyßer, S., Heßmann, P., & Wiltfang, J. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01099-x · Cited by 15
Szmulewicz, A., Wanis, K. N., Perlis, R. H., Hernández–Díaz, S., Öngür, D., & Hernán, M. Á. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.09.028 · Cited by 16
Medina-Rodriguez, E. M., Rice, K. C., Beurel, E., & Jope, R. S. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.08.022 · Cited by 15
Bursky, M., Egglefield, D. A., Schiff, S., Premnath, P. Y., & Sneed, J. R. (2022) · Brain Sciences · doi:10.3390/brainsci12050663 · Cited by 16
Can botulinum toxin improve mood in depressed patients?
Han, C., Park, G., Wang, S., Lee, S.-Y., Lee, S.-J., Bahk, W., & Pae, C. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.92 · Cited by 15
Batievsky, D., Weiner, M. D., Kaplan, S. B., Thase, M. E., Maglione, D. N., & Vidot, D. C. (2023) · Frontiers in Pain Research · doi:10.3389/fpain.2023.1127863 · Cited by 15
Zhang, J., Duan, J., Li, W., Wang, X., Ren, S., Ye, L., Liu, F., Tian, X., Xie, Y., Huang, Y., et al. (2025) · Science Advances · doi:10.1126/sciadv.adq0444 · Cited by 14
Lee, K. H., Bahk, W., Lee, S.-J., & Pae, C. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.4.621 · Cited by 15
NEUROPLASTICITY IN DEPRESSION: A NARRATIVE REVIEW WITH EVIDENCE-BASED INSIGHTS
Petra, Mudgal, S. K., Nath, S., Chaturvedi, J., Sharma, S. K., & Joshi, J. (2022) · Psychiatria Danubina · doi:10.24869/psyd.2022.390 · Cited by 14
Echegaray, M. V. F., Mello, R. P., Magnavita, G. M., Leal, G. C.-G., Correia‐Melo, F. S., Jesus‐Nunes, A. P., Vieira, F., Bandeira, I. D., Caliman‐Fontes, A. T., Telles, M., et al. (2025) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2022-0593 · Cited by 14
The possible place for psychedelics in pharmacotherapy of mental disorders
Wojtas, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00550-9 · Cited by 14
Novel rapid-acting antidepressants: molecular and cellular signaling mechanisms
Thomas, A. M., & Duman, R. S. (2017) · Neuronal Signaling · doi:10.1042/ns20170010 · Cited by 14
Botanas, C. J., Custodio, R. J. P., Kim, H. J., de la Peña, J. B., Sayson, L. V., Ortiz, D. M., Kim, M., Lee, H. J., Acharya, S., Kim, K., et al. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108619 · Cited by 14
Bansal, Y., Fee, C., Misquitta, K. A., Codeluppi-Arrowsmith, S. A., Sibille, E. L., Berman, R., Coric, V., Sanacora, G., & Banasr, M. (2023) · Complex Psychiatry · doi:10.1159/000529534 · Cited by 14
Ferber, S. G., Weller, A., Yadid, G., & Friedman, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041867 · Cited by 14
Cepeda, Y., Elizondo-Vega, R. J., Garrido, C., Tobar, C., Araneda, M., Oliveros-Matus, P., Órdenes, P., Pardo, C. C., Vidal, P. M., Luz‐Crawford, P., et al. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1406832 · Cited by 13
Zwiep, J. C., Lamers, F., Vinkers, C. H., van der Wee, N. J. A., Penninx, B. W. J. H., Nawijn, L., & Milaneschi, Y. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106240 · Cited by 13
Depresja — czy faktycznie zróżnicowana farmakoterapia?
Pełka-Wysiecka, J., & Samochowiec, J. (2014) · Psychiatria · Cited by 14
Filho, A. J. M. C., Mottin, M., Lós, D. B., Andrade, C. H., & Macêdo, D. S. (2022) · Biochimie · doi:10.1016/j.biochi.2022.07.015 · Cited by 13
Barzegari, A., Mahdirejei, H. A., Hanani, M., Esmaeili, M. H., & Salari, A. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114264 · Cited by 13
Excitatory amino acids in neurological and neurodegenerative disorders.
Flores, G., Negrete-Díaz, J. V., Carrión, M., Andrade‐Talavera, Y., Bello, S. A., Sihra, T. S., & Rodríguez-Moreno, A. (2011) · CABI eBooks · doi:10.1079/9781845937980.0427 · Cited by 14
Baik, S.-Y., Crabtree, B. F., & Gonzales, J. J. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2468-3 · Cited by 13
Ulbricht, C. M., Rothschild, A. J., & Lapane, K. L. (2016) · Journal of Women s Health · doi:10.1089/jwh.2015.5361 · Cited by 13
Anti-NMDA-receptor antibody in initial diagnosis of mood disorder
Kawai, H., Takaki, M., Sakamoto, S., Shibata, T., Tsuchida, A., Yoshimura, B., Yada, Y., Matsumoto, N., Sato, K., Abe, K., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.07.137 · Cited by 13
The emotional dance with depression: A longitudinal investigation of OULA® for depression in women
Hellem, T., Sung, Y., Ferguson, H., & Hildreth, L. A. (2020) · Journal of Bodywork and Movement Therapies · doi:10.1016/j.jbmt.2020.05.007 · Cited by 13
Is ketamine a litmus test for capacity in assisted dying with depression?
Rosenblat, J. D., & Li, M. (2020) · Psycho-Oncology · doi:10.1002/pon.5586 · Cited by 13
Kojic, M., Saelens, J., Kadriu, B., Zarate, C. A., & Kraus, C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_313 · Cited by 13
Evidence-Based Somatic Treatment of Depression in Adults
Carlat, D. J. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.002 · Cited by 14
An, J., Li, L., Wang, L., Su, Y., Wang, Y., Li, K., Zeng, Y., Kong, Q., Yan, C., & Si, T. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00884 · Cited by 13
Di Vincenzo, J. D., Lipsitz, O., Rodrigues, N. B., Lee, Y., Gill, H., Kratiuk, K., Subramaniapillai, M., Mansur, R., McIntyre, R. S., & Rosenblat, J. D. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.09.002 · Cited by 12
Qin, M., Wu, J., Zhou, Q., Liang, Z., & Su, Y. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.09.039 · Cited by 12
Rigdon, G. C., Prescott, Y., Hall, J. P., Abernathy, K., Raskin, J., & Wargin, W. A. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1488 · Cited by 12
Rosson, S., Bresolin, N., D’Amico, A., Denaro, L., Landi, A., Sambataro, F., & Pigato, G. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120483 · Cited by 12
León, B. E., Peyton, L., Essa, H., Wieden, T., Marion, N., Childers, W. E., Abou-Gharbia, M. A., & Choi, D. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109515 · Cited by 12
Lenze, E. J., Torous, J. B., & Areán, P. A. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01664-7 · Cited by 12
Kabotyanski, K. E., Najera, R. A., Banks, G. P., Sharma, H., Provenza, N. R., Hayden, B. Y., Mathew, S. J., & Sheth, S. A. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02951-7 · Cited by 13
The Use of Monoamine Oxidase Inhibitors in Primary Care
Culpepper, L. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11096su1c.06 · Cited by 12
Kaczmarczyk, M., Antosik-Wójcińska, A. Z., Dominiak, M., & Święcicki, Ł. (2020) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/115191 · Cited by 12
Narkose zur Elektrokrampftherapie
Grundmann, U., & Schneider, S. O. (2013) · Der Anaesthesist · doi:10.1007/s00101-013-2152-3 · Cited by 12
Butterfield, N. N., Luzon Rosenblut, C., Fava, M., Correll, C. U., Rothschild, A. J., Murrough, J. W., Mathew, S. J., Beatch, G. N., Grayson, C., Harden, C., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.14278 · Cited by 11
Self-citationHe, H., Cathomas, F., Parise, L. F., David, E., Rizk, M., Hawkins, K. A., Karpman, E., Russo, S. J., Guttman, E., & Murrough, J. W. (2026) · Molecular Psychiatry · doi:10.1038/s41380-025-03383-5 · Cited by 11
Chen, D. T.-L., Cheng, S., Chen, T., Chang, J. P., Hwang, B., Chang, H., Chuang, E. Y., Chen, C., & Su, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133622 · Cited by 11
Roberts, B., Cooper, Z., Landery, G., Stanley, S. H., Majda, B. T., Collins, K. R. L., Akkari, P. A., Hood, S. D., Rodger, J., & Rodger, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1526101 · Cited by 11
Strawbridge, R., Young, A. H., & Cleare, A. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00027-1 · Cited by 11
Pharmacogenomic Testing for Next-Step Antidepressant Selection: Still a Work in Progress
Iosifescu, D. V. (2022) · JAMA · doi:10.1001/jama.2022.10018 · Cited by 11
Vreijling, S. R., van Haeringen, M., Milaneschi, Y., Huider, F., Bot, M., Amin, N., Beulens, J. W. J., Bremmer, M. A., Elders, P. J. M., Galesloot, T. E., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.11.005 · Cited by 11
Issues in Adherence to Treatment With Monoamine Oxidase Inhibitors and the Rate of Treatment Failure
Cohen, L. J., & Sclar, D. A. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11096su1c.05 · Cited by 11
Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation
Leong, I. L., Ng, T. H., Sen, K., Burchill, E., Costello, H., Badenoch, J., Coebergh, J. W. W., McCutcheon, R. A., Nair, A., Browning, M. D., et al. (2025) · Brain · doi:10.1093/brain/awaf335 · Cited by 10
Rodek, P., Kowalczyk, M., Kowalski, J., Owczarek, A. J., Choręza, P. S., & Kucia, K. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195914 · Cited by 10
Systematic review of structured care pathways in major depressive disorder and bipolar disorder
Kim, H. K., Banik, S., Husain, M. I., Tang, V. M., Levitan, R. D., Daskalakis, Z. J., & Kloiber, S. M. (2023) · BMC Psychiatry · doi:10.1186/s12888-022-04379-z · Cited by 10
Atefi, A., Ghanaatpisheh, A., Fereidouni, M., Habibi, G., Niarad, F. T., & Aboutaleb, E. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.02.013 · Cited by 10
Novel Therapeutic Targets for Major Depressive Disorder
Lazar, M. A., & McIntyre, R. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00034-2 · Cited by 10
Rethinking the medication management of major depression
Mann, J. J., & Rizk, M. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2190886 · Cited by 10
Biopharmaceutical Characterization and Oral Efficacy of a New Rapid Acting Antidepressant Ro 25-6981
Yellepeddi, V., Zhudeva, M. Y., Movahedi, F., Vo, A., Phan, J., Kirsh, R. D., Rawlins, D. B., & Talbot, J. N. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.05.005 · Cited by 10
Sartori, D. P., de Oliveira, N. F., Valentim, J. T., Silva, D. M. A., Mallmann, A. S. V., Oliveira, I. C. M., Chaves, R., Capibaribe, V. C. C., de Carvalho, A. M. R., Rebouças, M. D. O., et al. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112487 · Cited by 10
Drake, C. L., Kalmbach, D. A., Cheng, P., Ahmedani, B. K., Peterson, E. L., Joseph, C. L. M., Roth, T. G., Kidwell, K., & Sagong, C. (2022) · Trials · doi:10.1186/s13063-022-06850-4 · Cited by 10
To Treat or Not to Treat: Psychosis, Palliative Care, and Ethics at the End-of-Life: A Case Analysis
GEPPERT, C. M. A., Rabjohn, P. A., & Vlaskovits, J. (2011) · Psychosomatics · doi:10.1016/j.psym.2010.12.003 · Cited by 11
Pharmacological Treatment of Major Depressive Disorder
Rosenblat, J. D., & McIntyre, R. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-58131-8.00008-2 · Cited by 10
Young, A. H., Llorca, P.-M., Fagiolini, A., Falkai, P., Cardoner, N., Nielsen, R. E., Blomqvist, O., Godinov, Y., Rive, B., Diels, J., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.124 · Cited by 9
Ceolato, C., Chevallier‐Collins, C., Clément, J., Charles, E., Lacroix, A., & Ranoux, D. (2024) · Depression and Anxiety · doi:10.1155/2024/1177925 · Cited by 9
Metadata
- Authors
- Gaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- National University of Singapore (SG)
- Venue
- Psychiatric Services
- Published
- 2009-11
- Volume
- 60
- Issue
- 11
- Pages
- 1439-1445
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W2095852687
- Cited by
- 661
- References
- 0
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 57 · 2023: 73 · 2022: 61 · 2021: 58 · 2020: 55 · 2019: 48 · 2018: 41 · 2017: 42 · 2016: 28 · 2015: 33 · 2014: 20 · 2013: 20 · 2012: 16
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatric Services (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Funders
- University of Texas Southwestern Medical Center
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- STAR*D, major depressive disorder, antidepressant treatment, treatment-resistant depression, remission, citalopram, antidepressant switching, antidepressant augmentation, primary care, psychiatric clinic
- MeSH terms
- Venlafaxine Hydrochloride, Adolescent, Adult, Aged, Cyclohexanols, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Primidone, Remission Induction, Time Factors, Citalopram, Cognitive Behavioral Therapy, Bupropion, Treatment Outcome, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Dopamine Uptake Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.